DMK Pharmaceuticals Corporation Common Stock
DMK was delisted on the 6th of February, 2024.
22 hedge funds and large institutions have $276K invested in DMK Pharmaceuticals Corporation Common Stock in 2023 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 6 increasing their positions, 10 reducing their positions, and 26 closing their positions.
40% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 10
53% less funds holding
Funds holding: 47 → 22 (-25)
91% less capital invested
Capital invested by funds: $3.2M → $276K (-$2.92M)
96% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 26
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
+$58.3K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$13.4K |
| 3 |
JP Morgan Chase
New York
|
+$7.17K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$824 |
| 5 |
Group One Trading
Chicago,
Illinois
|
+$60 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$1.68M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$264K |
| 3 |
State Street
Boston,
Massachusetts
|
-$55.1K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$37.9K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$28.4K |
DMK Hedge Fund Activity: Q2 2023 in Review
22 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in DMK Pharmaceuticals Corporation Common Stock (DMK) for Q2 2023, worth a combined $276K — down 91% from $3.2M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of DMK and 1 opened new positions — a net loss of 25 holders — while 10 trimmed existing stakes and 6 added.
The largest buyer was Cubist Systematic Strategies, opening a new position worth an estimated $58.3K. The largest seller was Armistice Capital, exiting entirely with an estimated $1.68M sold.
- 22 institutional investors held DMK Pharmaceuticals Corporation Common Stock (DMK) as of Q2 2023, down from 47 in Q1 2023.
- Funds reported $276K of DMK Pharmaceuticals Corporation Common Stock stock for Q2 2023, down 91% quarter-over-quarter.
- 1 fund opened new DMK Pharmaceuticals Corporation Common Stock positions in Q2 2023 and 26 closed out, a net change of -25 holders.
- The largest DMK Pharmaceuticals Corporation Common Stock buyer in Q2 2023 was Cubist Systematic Strategies, an estimated $58.3K added.
- The largest DMK Pharmaceuticals Corporation Common Stock seller in Q2 2023 was Armistice Capital, an estimated $1.68M sold.
Based on aggregated 13F filings for Q2 2023.